Design and SAR of Withangulatin A Analogues that Act as Covalent TrxR Inhibitors through the Michael Addition Reaction Showing Potential in Cancer Treatment
作者:Cheng Wang、Shang Li、Jinhua Zhao、Huali Yang、Fucheng Yin、Ming Ding、Jianguang Luo、Xiaobing Wang、Lingyi Kong
DOI:10.1021/acs.jmedchem.0c01128
日期:2020.10.8
targeting, we designed and prepared 41 semisynthetic analogues of WA. Biological evaluation indicated that the most promising compound 13a displayed the most significant effect on HT-29 cells (human colon cancer cells) (IC50 = 0.08 μM). A structure–activity relationship study indicated that α,β-unsaturated ketones and ester are necessary groups, allowing 13a to undergo Michael addition reactions with mercaptan
硫氧还蛋白系统在癌细胞中起重要作用。抑制硫氧还蛋白还原酶(TrxR)已经成为选择性靶向癌细胞的有效策略。Withangulatin A(WA)是从酸浆(Solanaceae)整个草药中提取的天然产物,具有强大的抗癌活性和其他多种药理活性。为了提高活性和针对性,我们设计并制备了WA的41种半合成类似物。生物学评估表明,最有前途的化合物13a对HT-29细胞(人结肠癌细胞)显示出最显着的作用(IC 50= 0.08μM)。构效关系研究表明,α,β-不饱和酮和酯是必需基团,使13a与硫醇和硒醇进行迈克尔加成反应。液相色谱-质谱(LC-MS)分析证实,TrxR氧化还原中心的13a修饰的硒代半胱氨酸498(U)残基导致酶抑制。因此,化合物13a充当新型TrxR抑制剂,可能是有希望的癌症干预候选药物。